New drug combo aims to control Hard-to-Treat hodgkin lymphoma
Disease control
Recruiting now
This study tests a combination of two drugs, nivolumab and ruxolitinib, in people with classical Hodgkin lymphoma that has returned or not responded to prior treatments. The goal is to find the safest dose of ruxolitinib when given with nivolumab and to see how well the combinati…
Phase: PHASE1, PHASE2 • Sponsor: Veronika Bachanova • Aim: Disease control
Last updated May 18, 2026 12:07 UTC